BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 18561588)

  • 1. Psoriasis and the metabolic syndrome.
    Gottlieb AB; Dann F; Menter A
    J Drugs Dermatol; 2008 Jun; 7(6):563-72. PubMed ID: 18561588
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Psoriasis comorbidities.
    Gottlieb AB; Chao C; Dann F
    J Dermatolog Treat; 2008; 19(1):5-21. PubMed ID: 18273720
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Psoriasis and metabolic syndrome.
    Takahashi H; Iizuka H
    J Dermatol; 2012 Mar; 39(3):212-8. PubMed ID: 22035413
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis.
    Sommer DM; Jenisch S; Suchan M; Christophers E; Weichenthal M
    Arch Dermatol Res; 2006 Dec; 298(7):321-8. PubMed ID: 17021763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association between psoriasis and the metabolic syndrome. A cross-sectional study.
    Cohen AD; Sherf M; Vidavsky L; Vardy DA; Shapiro J; Meyerovitch J
    Dermatology; 2008; 216(2):152-5. PubMed ID: 18216477
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term prognosis in patients with psoriasis.
    Gulliver W
    Br J Dermatol; 2008 Aug; 159 Suppl 2():2-9. PubMed ID: 18700909
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of tumor necrosis factor-alpha blockade on metabolic syndrome components in psoriasis and psoriatic arthritis and additional lessons learned from rheumatoid arthritis.
    Channual J; Wu JJ; Dann FJ
    Dermatol Ther; 2009; 22(1):61-73. PubMed ID: 19222518
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control study.
    Gisondi P; Tessari G; Conti A; Piaserico S; Schianchi S; Peserico A; Giannetti A; Girolomoni G
    Br J Dermatol; 2007 Jul; 157(1):68-73. PubMed ID: 17553036
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Psoriasis and the metabolic syndrome.
    Alsufyani MA; Golant AK; Lebwohl M
    Dermatol Ther; 2010; 23(2):137-43. PubMed ID: 20415820
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The concept of psoriasis as a systemic inflammation: implications for disease management.
    Reich K
    J Eur Acad Dermatol Venereol; 2012 Mar; 26 Suppl 2():3-11. PubMed ID: 22356630
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessor-blinded study of the metabolic syndrome and surrogate markers of increased cardiovascular risk in children with moderate-to-severe psoriasis compared with age-matched population of children with warts.
    Volf EM; Levine DE; Michelon MA; Au SC; Patvardhan E; Dumont N; Loo DS; Kuvin J; Gottlieb AB
    J Drugs Dermatol; 2011 Aug; 10(8):900-1. PubMed ID: 21818512
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Psoriasis and the metabolic syndrome.
    Cohen AD; Gilutz H; Henkin Y; Zahger D; Shapiro J; Bonneh DY; Vardy DA
    Acta Derm Venereol; 2007; 87(6):506-9. PubMed ID: 17989888
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Psoriasis and atherothrombotic diseases: disease-specific and non-disease-specific risk factors.
    Gisondi P; Girolomoni G
    Semin Thromb Hemost; 2009 Apr; 35(3):313-24. PubMed ID: 19452407
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Metabolic disorders in patients with psoriasis].
    Sikora-Grabka E; Adamczak M; Wiecek A
    Przegl Lek; 2011; 68(12):1193-8. PubMed ID: 22519279
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Psoriasis independently associated with hyperleptinemia contributing to metabolic syndrome.
    Chen YJ; Wu CY; Shen JL; Chu SY; Chen CK; Chang YT; Chen CM
    Arch Dermatol; 2008 Dec; 144(12):1571-5. PubMed ID: 19075139
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The metabolic syndrome and cardiometabolic risk: scope of the problem and current standard of care.
    Lender D; Sysko SK
    Pharmacotherapy; 2006 May; 26(5 Pt 2):3S-12S. PubMed ID: 16637782
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Obesity in psoriasis: the metabolic, clinical and therapeutic implications. Report of an interdisciplinary conference and review.
    Sterry W; Strober BE; Menter A;
    Br J Dermatol; 2007 Oct; 157(4):649-55. PubMed ID: 17627791
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical aspects and comorbidities of psoriasis.
    Ayala F; Ayala F
    J Rheumatol Suppl; 2009 Aug; 83():19-20. PubMed ID: 19661531
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The metabolic syndrome and cardiovascular disease.
    Vitarius JA
    Mt Sinai J Med; 2005 Jul; 72(4):257-62. PubMed ID: 16021320
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolic comorbidities and psoriasis.
    Gisondi P; Ferrazzi A; Girolomoni G
    Acta Dermatovenerol Croat; 2010; 18(4):297-304. PubMed ID: 21251450
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.